IRadimed drops about 11% after Q3 2026 results miss elevated expectations
FROM THE WIRE · FINANCE.YAHOO.COM
IRADIMED came into this earnings season priced for excellence, trading on a rich P/E and riding years of steady profit expansion. Then Q3 2026 hit and the stock dropped about 11% in a single session. That sharp move jars with what the report actually showed. Revenue reached a…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe stock, priced on a rich P/E, fell despite record revenue.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 2026 revenue was a record US$24.2 million versus US$21.2 million.
- 02Basic earnings per share were roughly US$0.51.
- 03The stock dropped about 11% in a single session.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets